Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3296598 | 0.94 | LMNA (0.35) | LMNAMAPK1ALDH1A1KDM4EHTT | |
| Trifluoroacetic Acid SCHEMBL3288201 | 0.88 | KDM4E (0.37) | LMNAMAPK1ALDH1A1KDM4EHTT | |
| SCHEMBL3291767 | 0.84 | PDE4A (0.33) | LMNAMAPK1ALDH1A1KDM4EHTT | |
| SCHEMBL3980217 | 0.81 | LMNA (0.48) | LMNAMAPK1ALDH1A1KDM4EHTT | |
| Trifluoroacetic Acid SCHEMBL3296590 | 0.80 | KDM4E (0.40) | LMNAALDH1A1KDM4EHTTHPGD | |
| SCHEMBL4391029 | 0.76 | LMNA (0.43) | LMNAMAPK1ALDH1A1KDM4EHTT | |
| SCHEMBL5479980 | 0.76 | LMNA (0.41) | LMNAALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL3819899 | 0.72 | LMNA (0.45) | LMNAMAPK1ALDH1A1KDM4EHTT | |
| Trifluoroacetic Acid SCHEMBL3291762 | 0.71 | KDM4E (0.37) | LMNAMAPK1ALDH1A1KDM4EHTT | |
| SCHEMBL3296288 | 0.71 | BCHE (0.35) | LMNAALDH1A1KDM4EHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718621-B2 | Macrolones—amino substituted quinolones | GLAXO GROUP LTD. (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| EP-1824870-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050942-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | MRPL21, Q6ZSR9, QARS1 | LMNA 1318/4885MAPK1 2832/4885ALDH1A1 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.